AzTrials
AzTrials

Nasopharyngeal NeoplasmsNCT01257100

Environmental and Genetic Determinants of NPC

An observational study of Nasopharyngeal Neoplasms and Herpesvirus 4, Human, run by National Cancer Institute (NCI) at 6 sites in Taiwan.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Background: Nasopharyngeal carcinoma (NPC) a common malignant tumor in southern China and Southeast Asia. Infection with Epstein-Barr virus is believed to be necessary for the development of NPC; non-viral environmental factors, such as dietary consumption of nitrosamines, cigarette smoking, betel nut chewing, wood… Read more about this study

Who is it for?
Ages 21 to 100 years
How many people
3,500 participants
Where
6 sitesTaiwan
Study dates
8 Dec 2010to 2 Jun 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: This is a hospital based case control population

Who may be able to join

  • Eligibility criteria for cases:
  • Incident diagnosis of NPC between 2010-2015
  • Age greater than or equal to 21 years at NPC diagnosis
  • Histologically confirmed
  • Resident of northern Taiwan greater than or equal to 6 months
  • Eligibility criteria for controls:
  • Resident of northern Taiwan greater than or equal to 6 months
  • Matched to case based on age at diagnosis, gender, and ethnicity

Who cannot join

  • Clinic attendance due to conditions associated with EBV or smoking

Trial locations and contacts

6 sites in 1 country.

6 sites in 1 country

Taiwan6 sites
  • Academia Sinica 128 Academia Road

    Taipei

  • Cathay General Hospital 280 Renai Rd, Section 4

    Taipei

  • Far Easter Memorial Hospital 21, NanYa S. Rd, Section 2, Ban-Chiao

    Taipei

  • Koo Foundation Sun Yat-Sen Cancer Center

    Taipei

  • MacKay Memorial Hospital No 92, Section 2, Zhongshan N. Rd, Zhongshan Dist

    Taipei

  • National Taiwan University Hospital

    Taipei

Other trials in Taiwan

About this study

Background:

  • Nasopharyngeal carcinoma (NPC) a common malignant tumor in southern China and Southeast Asia. Infection with Epstein-Barr virus is believed to be necessary for the development of NPC; non-viral environmental factors, such as dietary consumption of nitrosamines, cigarette smoking, betel nut chewing, wood dust exposure and possibly exposure to formaldehyde, have been implicated in the disease. Genetic susceptibility may also play an important role in the development of NPC. However, more information is needed on the connections between genetic and environmental factors in NPC, particularly in areas where the cancer risk appears to be greatest.
Read more

Objectives:

  • To examine the main effects of genetic factors and environmental exposures (e.g., cigarette smoking, betel nut chewing, formaldehyde, wood dust) on nasopharyngeal carcinoma risk.

Eligibility:

  • Cases: Individuals at least 21 years of age who have been diagnosed with NPC at one of the participating hospitals and have been residents of northern Taiwan for at least 6 months.
  • Controls: Hospital patients with diseases other than NPC at least 21 years of age, matched to NPC patients based on hospital, age at diagnosis, gender, and ethnicity.

Design:

  • This study involves a risk factor interview, medical record abstraction and biological sample collection.
  • Participants will respond to interview questions about their lifestyle and risk factors thought to be involved in NPC development.
  • All participants will provide blood and saliva samples for study. Participants who have been diagnosed with NPC will also provide consent to allow researchers to study tissue samples taken during tumor biopsies or surgeries.
  • Treatment will not be provided as part of this protocol.
Read the detailed description

Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in southern China and Southeast Asia. While infection with Epstein-Barr Virus (EBV) is believed to be necessary for the development of NPC, non-viral environmental factors have also been implicated in the carcinogenesis of NPC including consumption of salted fish and other nitrosamine containing preserved foods, formaldehyde and wood dust exposure, cigarette smoking, and betel nut chewing. In addition to environmental factors, it is widely accepted that genetic susceptibility plays an important role in the pathogenesis of NPC. Polymorphisms in genes involved in antigen presentation, nitrosamine metabolism and DNA repair have been suggested to be associated with NPC risk, and various chromosomal regions linked to NPC development have been reported. Two recently completed NPC GWAS have reported that the strongest evidence for disease association is observed for SNPs located on the 3.6 Mb Major Histocompatibility Complex (MHC) region on chromosome 6p21 where human leukocyte antigen (HLA) genes are located. These associations highlight the role of both environmental exposures and genomic variation in the etiology of NPC. However, the specific role of EBV on NPC pathogenesis is not completely understood and studies to date have had difficulty pinpointing the specific genetic factors involved in NPC pathogenesis due to the complexity of the MHC region and limited sample size of candidate gene studies.

DCEG investigators and their Taiwan colleagues have a longstanding history of studies to elucidate the role of environmental and genetic factors associated with NPC. A case-control study (375 cases; 327 controls) was conducted in the early 1990s and was followed by a large multiplex family study that was completed in 2006 (358 families; 3,216 individuals). Results from these studies have provided a substantial portion of the epidemiological evidence regarding factors linked to NPC development to date.

At this time, we propose a new case-control study in Taiwan designed to 1) comprehensively evaluate environmental risk factors for NPC; 2) systematically evaluate genetic risk factors for NPC for which previous GWAS and candidate-gene studies have suggested an association; and 3) explore gene-gene and gene-environment interactions for strong main effects identified in our study. In total, up to 2000 cases and 2000 controls are expected to be recruited from five participating hospitals in Northern Taiwan. Cases will consist of 550 incident cases ascertained retrospectively and 1350 incident cases ascertained prospectively. Controls will be hospital based; they will be frequency matched (1:1) to cases on age, gender and ethnicity, and will exclude individuals referred to the participating hospitals due to conditions associated with known NPC risk factors.

This project is a collaborative effort between investigators in Taiwan and at the NCI. Investigators in Taiwan will fund the field recruitment and data collection effort. Results from this study have the potential to further clarify currently controversial environmental risk factors as well as elucidate genetic factors of NPC.

Keywords
Nasopharyngeal Carcinoma, Epstein-Barr Virus, NPC
Medical subject headings
Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Nasopharyngeal Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01257100
Study groupRoleWhat they receive
Cases with NPCCases with NPC
Hospital based controlsHospital based controls

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Nasopharyngeal carcinoma

    NPC diagnosis

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2010 (estimated)
  2. Study start8 Dec 2010
  3. Primary completion2 Jun 2020
  4. Study completion2 Jun 2020

Why it stopped: Determined not to be Human Subject Research

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
3,500 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01257100
Sponsor's protocol ID
999911040
Other IDs
11-C-N040
Status last verified
Jun 2020
First submitted
8 Dec 2010
Last updated
4 Jun 2020
Results posted
No

Publications

  • Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu MC, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: salted fish and other dietary exposures. Int J Cancer. 1998 Jul 17;77(2):228-35. doi: 10.1002/(sici)1097-0215(19980717)77:23.0.co;2-7.

    PubMed 9650558
  • Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang T, Liu ET, Liu J, Zeng YX. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010 Jul;42(7):599-603. doi: 10.1038/ng.601. Epub 2010 May 30.

    PubMed 20512145
  • Blair A, Saracci R, Stewart PA, Hayes RB, Shy C. Epidemiologic evidence on the relationship between formaldehyde exposure and cancer. Scand J Work Environ Health. 1990 Dec;16(6):381-93. doi: 10.5271/sjweh.1767.

    PubMed 2284588

Questions about this trial

What is this clinical trial studying?

An observational study of Nasopharyngeal Neoplasms and Herpesvirus 4, Human, run by National Cancer Institute (NCI) at 6 sites in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 4 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Determined not to be Human Subject Research). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Nasopharyngeal carcinoma. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01257100, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in